Evidence Table E2. CONTINUOUS outcomes for class RETINOID (TOPICAL).

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	E.01.01			**Adapalene (0.03%)**		**Adapalene (0.1%)**		
338 ↑ Parallel	N=72 Mild/mod/sev	**Inflammatory change (%)** Count location: Face.	Short (4)	Percent change: -8		Percent change: -25		
78	N=89	**Total lesions change (%)** Count location: Face excluding nose.	Short (4)	Percent change: -30		Percent change: -45		
338	N=72	**Inflammatory change (%)** Count location: Face.	Mid (12)	Percent change: -45		Percent change: -65	*NS*	**0.05**
		Non-inflammatory (count)	Mid (12)	Raw count: 28 (22.5)		Raw count: 20 (26.9)	*NS*	**0.05**
		Severity (leeds)	Mid (12)	Measure: 1 (0.49)		Measure: 0 (0.25)		**0.05**
78	N=89	**Total lesions change (%)** Count location: Face excluding nose.	Mid (12)	Percent change: -53		Percent change: -72		
	E.01.01			**Adapalene-delayed**		**Adapalene-immediate**		
92 ↓ Parallel Mild/mod	N=25 split face	**Dryness (score)**	Short (2)	Measure: 1		Measure: 1		**NS**
		Erythema (score)	Short (2)	Measure: 1		Measure: 1		**NS**
	E.01.02			**Adapalene**		**Tretinoin**		
93 ↑ Parallel Mild/mod	N=100 split face	**Desquamation**	Short (0)	Measure: 0 (0.24)		Measure: 0 (0.2)		**1**
		Dryness (score)	Short (0)	Measure: 0 (0.3)		Measure: 0 (0.31)		**1**
		Erythema (score)	Short (0)	Measure: 1 (0.52)		Measure: 1 (0.52)		**NS**
		Stinging/burning	Short (0)	Measure: 0 (0.)		Measure: 0 (0.)		**1**
		Total adverse skin symptom (score)	Short (0)	Measure: 1 (0.7)		Measure: 1 (0.68)		**NS**
		Desquamation	Short (4)	Measure: 0 (0.71)		Measure: 1 (0.87)		**0.034**
		Erythema (score)	Short (4)	Measure: 2 (0.87)		Measure: 2 (0.52)		**0.021**
100 Parallel	N=297 Mod	**Inflammatory (count)** Count location: Entire face. Baseline counts: 26 (Target) / 26 (Comparator)	Short (4)	Percent Change*: -23		Percent Change*: -19		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
80 ↑ Parallel	N=268	**Inflammatory change (%)** Count location: Face excluding nose.	Short (4)	Percent change: -39		Percent change: -35		
140 ↑ Parallel	N=105 Mild/mod	**Inflammatory change (%)**	Short (4)	Percent change: -45		Percent change: -35		**NS**
93 Parallel Mild/mod	N=100 split face	**Local reactions/Dryness (score)**	Short (4)	Measure: 1 (0.78)		Measure: 1 (0.89)		**0.017**
100 Parallel	N=297 Mod	**Non-inflammatory (count)** Count location: Entire face. Baseline counts: 50 (Target) / 52 (Comparator)	Short (4)	Percent Change*: -28		Percent Change*: -25		**NS**
80 ↑ Parallel	N=268	**Non-inflammatory change (%)** Count location: Face excluding nose.	Short (4)	Percent change: -30		Percent change: -16		
140 ↑ Parallel	N=105 Mild/mod	**Non-inflammatory change (%)**	Short (4)	Percent change: -41		Percent change: -42		**NS**
		Severity (leeds) [per protocol]	Short (4)	Measure: 1 (0.7)		Measure: 1 (0.7)		**NS**
		Severity change (leeds %) [per protocol]	Short (4)	Measure: -42 (36.4)		Measure: -34 (36.7)		**NS**
93 Parallel Mild/mod	N=100 split face	**Stinging/burning**	Short (4)	Measure: 0 (0.82)		Measure: 1 (0.85)		**NS**
		Total adverse skin symptoms (score)	Short (4)	Measure: 4 (2.33)		Measure: 5 (2.64)		**0.011**
306 ↑ Parallel	N=288 Mod	**% Burning grade I**	Mid (12)	Measure: 3		Measure: 8		**NS**
		% Dryness grade I	Mid (12)	Measure: 36		Measure: 48		**0.05**
		% Erythema grade I	Mid (12)	Measure: 35		Measure: 45		**0.05**
		% Scaling grade	Mid (12)	Measure: 22		Measure: 42		**0.05**
100 ↑	N=297	**Inflammatory (count)** Count location: Entire face. Baseline counts: 26 (Target) / 26 (Comparator)	Mid (12)	Percent Change*: -42		Percent Change*: -46		**NS**
		Inflammatory change (%) Count location: Entire face.	Mid (12)	Percent change: -47		Percent change: -50		**NS**
140 Parallel	N=105 Mild/mod	**Inflammatory change (%)**	Mid (12)	Percent change: -58		Percent change: -61		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
80 ↑ Parallel	N=268	**Inflammatory change (%)** Count location: Face excluding nose.	Mid (12)	Percent change: -65		Percent change: -65		
306 Parallel	N=288 Mod	**Inflammatory change (%)**	Mid (12)	Percent change: -48		Percent change: -38		**0.01**
100 ↑	N=297	**Non-inflammatory (count)** Count location: Entire face. Baseline counts: 50 (Target) / 52 (Comparator)	Mid (12)	Percent Change*: -56		Percent Change*: -52		**NS**
306 ↑	N=288	**Non-inflammatory change (%)**	Mid (12)	Percent change: -46		Percent change: -33		**0.05**
80 Parallel	N=268	**Non-inflammatory change (%)** Count location: Face excluding nose.	Mid (12)	Percent change: -55		Percent change: -60		
100 ↑ Parallel	N=297 Mod	**Non-inflammatory change (%)** Count location: Entire face.	Mid (12)	Percent change: -57		Percent change: -54		**NS**
140 Parallel	N=105 Mild/mod	**Non-inflammatory change (%)**	Mid (12)	Percent change: -50		Percent change: -61		**NS**
100 Parallel	N=297 Mod	**Severity (leeds)** Count location: Entire face.	Mid (12)	Measure: 1	*.001*	Measure: 1	*.001*	**NS**
140 Parallel	N=105 Mild/mod	**Severity (leeds) [intention to treat]**	Mid (12)	Measure: 1 (0.6)		Measure: 1 (0.6)		**NS**
		Severity (leeds) [per protocol]	Mid (12)	Measure: 1 (0.6)		Measure: 1 (0.4)		**NS**
		Severity change (leeds %) [intention to treat]	Mid (12)	Measure: -51 (36.6)		Measure: -62 (31.3)		**NS**
		Severity change (leeds %) [per protocol]	Mid (12)	Measure: -56 (36.1)		Measure: -72 (21.2)		**NS**
100 Parallel	N=297 Mod	**Total lesions change (%)** Count location: Entire face.	Mid (12)	Percent change: -54		Percent change: -52		**NS**
306 ↑	N=288	**Total lesions change (%)**	Mid (12)	Percent change: -49		Percent change: -37		**0.01**
	E.01.02			**Adapalene (0.03%)**		**Tretinoin**		
338 ↑ Parallel	N=72 Mild/mod/sev	**Inflammatory change (%)** Count location: Face.	Short (4)	Percent change: -8		Percent change: 3		
78	N=89	**Total lesions change (%)** Count location: Face excluding nose.	Short (4)	Percent change: -30		Percent change: -50		
338	N=72	**Inflammatory change (%)** Count location: Face.	Mid (12)	Percent change: -45		Percent change: -42		**0.05**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
338 ↑ Parallel	N=72 Mild/mod/sev	**Non-inflammatory (count)** Count location: Face.	Mid (12)	Raw count: 28 (22.5)		Raw count: 17 (10.8)	*NS*	**0.05**
		Severity (leeds)	Mid (12)	Measure: 1 (0.49)		Measure: 1 (0.83)		**0.05**
78	N=89	**Total lesions change (%)** Count location: Face excluding nose.	Mid (12)	Percent change: -53		Percent change: -78		
	E.01.02			**Adapalene (0.1%)**		**Tretinoin**		
338 ↑ Parallel	N=72 Mild/mod/sev	**Inflammatory change (%)** Count location: Face.	Short (4)	Percent change: -25		Percent change: 3		
78	N=89	**Total lesions change (%)** Count location: Face excluding nose.	Short (4)	Percent change: -45		Percent change: -50		
		Inflammatory (count) Baseline counts: 35 (Target) / 41 (Comparator)	Mid (12)	Percent Change*: -69		Percent Change*: -73		
338	N=72	**Inflammatory change (%)** Count location: Face.	Mid (12)	Percent change: -65	*NS*	Percent change: -42		**0.05**
		Non-inflammatory (count)	Mid (12)	Raw count: 20 (26.9)	*NS*	Raw count: 17 (10.8)	*NS*	**NS***
78	N=89	**Non-inflammatory (count)** Count location: Face excluding nose. Baseline counts: 60 (Target) / 88 (Comparator)	Mid (12)	Percent Change*: -77		Percent Change*: -81		
338	N=72	**Severity (leeds)** Count location: Face.	Mid (12)	Measure: 0 (0.25)		Measure: 1 (0.83)		**NS**
78	N=89	**Severity (leeds)** Count location: Face excluding nose.	Mid (12)	Measure: 0		Measure: 1		**0.01**
		Total lesions change (%)	Mid (12)	Percent change: -72		Percent change: -78		
	E.02.01			**Isotretinoin**		**Vehicle**		
173 ↑ Parallel	N=77 Mild/mod	**Inflammatory (count)** Count location: Face. Baseline counts: 40 (Target) / 44 (Comparator)	Short (4)	Percent Change*: -05	*NS*	Percent Change*: -05	*NS*	**"significant"**
		Non-inflammatory (count) Count location: Face. Baseline counts: 45 (Target) / 49 (Comparator)	Short (4)	Percent Change*: -16	*.05*	Percent Change*: 02		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
173 ↑ Parallel	N=77 Mild/mod	**Severity (leeds)** Count location: Face.	Short (4)	Measure: 1	*NS*	Measure: 1	*NS*	**NS**
54 Parallel	N=313	**Inflammatory change (%)** Between P-value: no P value given.	Short (5)	Percent change: -25		Percent change: -15		**"significant"**
		Non-inflammatory change (%)	Short (5)	Percent change: -26		Percent change: -17		**NS**
		Severity change (cook %)	Short (5)	Measure: -18		Measure: -11		**NS**
		Inflammatory change (%) Between P-value: no P value given.	Mid (11)	Percent change: -50		Percent change: -23		**"significant"**
		Non-inflammatory change (%)	Mid (11)	Percent change: -36		Percent change: -13		**"significant"**
		Severity change (cook %)	Mid (11)	Measure: -33		Measure: -18		**"significant"**
173 Parallel	N=77 Mild/mod	**Inflammatory (count)** Count location: Face. Baseline counts: 40 (Target) / 44 (Comparator)	Mid (12)	Percent Change*: -33	*.01*	Percent Change*: 09	*NS*	**0.01**
		Non-inflammatory (count) Count location: Face. Baseline counts: 45 (Target) / 49 (Comparator)	Mid (12)	Percent Change*: -47	*.01*	Percent Change*: 06	*NS*	**0.01**
		Severity (leeds) Count location: Face.	Mid (12)	Measure: 0	*.01*	Measure: 1		**0.05**
54 Parallel	N=313	**Inflammatory change (%)** Between P-value: no P value given.	Long (14	Percent change: -55		Percent change: -25		**"significant"**
		Non-inflammatory change (%)	Long (14	Percent change: -46		Percent change: -14		**"significant"**
		Severity change (cook %)	Long (14	Measure: -40		Measure: -20		**"significant"**
	E.02.01			**Isotretinoin (0.05%)**		**Vehicle**		
202 Parallel	N=82 Mild/mod	**Closed comedones (count)** Count location: Face. Baseline counts: 23 (Target) / 18 (Comparator)	Short (4)	Percent Change*: -19	*NS*	Percent Change*: 11	*NS*	**NS***
		Papules (count) Count location: Face. Baseline counts: 23 (Target) / 20 (Comparator)	Short (4)	Percent Change*: -26	*.01*	Percent Change*: -30	*.01*	**NS***

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
202 Parallel	N=82 Mild/mod	**Closed comedones (count)** Count location: Face. Baseline counts: 23 (Target) / 18 (Comparator)	Mid (12)	Percent Change*: -47	*.01*	Percent Change*: -14	*NS*	**NS***
		Papules (count) Count location: Face. Baseline counts: 23 (Target) / 20 (Comparator)	Mid (12)	Percent Change*: -34	*.001*	Percent Change*: -49	*.01*	**NS***
	E.02.01			**Isotretinoin (0.1%)**		**Vehicle**		
202 Parallel	N=82 Mild/mod	**Closed comedones (count)** Count location: Face. Baseline counts: 21 (Target) / 18 (Comparator)	Short (4)	Percent Change*: -20	*NS*	Percent Change*: 11	*NS*	**NS***
		Papules (count) Count location: Face. Baseline counts: 23 (Target) / 20 (Comparator)	Short (4)	Percent Change*: -32	*.01*	Percent Change*: -30	*.01*	**NS***
		Closed comedones (count) Count location: Face. Baseline counts: 21 (Target) / 18 (Comparator)	Mid (12)	Percent Change*: -46	*.01*	Percent Change*: -14	*NS*	**NS***
		Papules (count) Count location: Face. Baseline counts: 23 (Target) / 20 (Comparator)	Mid (12)	Percent Change*: -60	*.01*	Percent Change*: -49	*.01*	**NS***
	E.02.02			**Isotretinoin**		**Benzoyl peroxide**		
173 ↑ Parallel	N=77 Mild/mod	**Inflammatory (count)** Count location: Face. Baseline counts: 40 (Target) / 44 (Comparator)	Short (4)	Percent Change*: -05	*NS*	Percent Change*: -43		**"significant"**
		Non-inflammatory (count) Count location: Face. Baseline counts: 45 (Target) / 48 (Comparator)	Short (4)	Percent Change*: -16	*.05*	Percent Change*: -23	*.05*	
		Severity (leeds) Count location: Face.	Short (4)	Measure: 1	*NS*	Measure: 1	*.01*	**NS**
		Inflammatory (count) Count location: Face. Baseline counts: 40 (Target) / 44 (Comparator)	Mid (12)	Percent Change*: -33	*.01*	Percent Change*: -52	*.01*	**0.01**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
173 ↑ Parallel	N=77 Mild/mod	**Non-inflammatory (count)** Count location: Face. Baseline counts: 45 (Target) / 48 (Comparator)	Mid (12)	Percent Change*: -47	*.01*	Percent Change*: -52	*.01*	**0.01**
		Severity (leeds) Count location: Face.	Mid (12)	Measure: 0	*.01*	Measure: 0	*.01*	**0.05**
	E.02.03			**Isotretinoin (0.05%)**		**Isotretinoin (0.1%)**		
202 Parallel	N=82 Mild/mod	**Closed comedones (count)** Count location: Face. Baseline counts: 23 (Target) / 21 (Comparator)	Short (4)	Percent Change*: -19	*NS*	Percent Change*: -20	*NS*	**NS***
		Papules (count) Count location: Face. Baseline counts: 23 (Target) / 23 (Comparator)	Short (4)	Percent Change*: -26	*.01*	Percent Change*: -32	*.01*	**NS***
		Closed comedones (count) Count location: Face. Baseline counts: 23 (Target) / 21 (Comparator)	Mid (12)	Percent Change*: -47	*.01*	Percent Change*: -46	*.01*	**NS***
		Papules (count) Count location: Face. Baseline counts: 23 (Target) / 23 (Comparator)	Mid (12)	Percent Change*: -34	*.001*	Percent Change*: -60	*.01*	**NS***
	E.02.04			**Isotretinoin**		**Tretinoin**		
90 ↑ Parallel	N=30 Mod	**Comedones (count)** Baseline counts: 40 (Target) / 33 (Comparator)	Short (4)	Percent Change*: -50		Percent Change*: -39		
		Inflammatory (count) Baseline counts: 13 (Target) / 13 (Comparator)	Short (4)	Percent Change*: -54		Percent Change*: -62		
		Comedones (count) Baseline counts: 40 (Target) / 33 (Comparator)	Mid (12)	Percent Change*: -78		Percent Change*: -70		
98 Parallel	N=18	**Comedones change (%)**	Mid (12)	Percent change: -37 (49.)	*sig*	Percent change: -32 (55.)	*sig*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
90 ↑ Parallel	N=30 Mod	**Inflammatory (count)** Baseline counts: 13 (Target) / 13 (Comparator)	Mid (12)	Percent Change*: -77		Percent Change*: -77		
98 Parallel	N=18	**Inflammatory change (%)**	Mid (12)	Percent change: -57 (25.)	*.01*	Percent change: -46 (29.)	*.01*	**NS**
		Total lesions change (%)	Mid (12)	Percent change: -51 (27.)		Percent change: -47 (37.)		**NS**
	E.03.01			**Motretinide**		**Vehicle**		
61 ↓ Parallel	N=19	**Comedones change (count)** Baseline counts: 9 (Target) / 9 (Comparator)	Short (4)	Percent change*: -33	*.05*	Percent change*: -11	*NS*	**NS**
		Total lesions change (count) Baseline counts: 12 (Target) / 16 (Comparator)	Short (4)	Percent change*: -42	*.01*	Percent change*: -13	*NS*	**NS**
		Comedones change (count) Baseline counts: 9 (Target) / 9 (Comparator)	Mid (7)	Percent change*: -67	*.05*	Percent change*: -11	*NS*	**NS**
		Total lesions change (count) Baseline counts: 12 (Target) / 16 (Comparator)	Mid (7)	Percent change*: -75	*.01*	Percent change*: -23	*NS*	**NS**
	E.03.02			**Motretinide (bid)**		**Motretinide (qd)**		
253 ↑ Parallel	N=60 Mod/sev	**Papules (count)** Baseline counts: 9 (Target) / 10 (Comparator)	Mid (8)	Percent Change*: -56	*.005*	Percent Change*: -50	*.01*	**NS**
		Pustules (count) Baseline counts: 11 (Target) / 10 (Comparator)	Mid (8)	Percent Change*: -64	*.001*	Percent Change*: -70	*.01*	**NS**
	E.03.03			**Motretinide**		**Tretinoin**		
59 ↑ Parallel	N=37 Mild	**Total lesions change (count/median)** Count location: Worst area/5cm diameter.	Mid (8)	Measure: -5	*.01*	Measure: -8	*.01*	**NS**
	E.03.03			**Motretinide (bid)**		**Tretinoin**		
253 ↑ Parallel	N=60 Mod/sev	**Papules (count)** Baseline counts: 9 (Target) / 7 (Comparator)	Mid (8)	Percent Change*: -56	*.005*	Percent Change*: -71	*.001*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
253 ↑ N=60 Parallel Mod/sev		**Pustules (count)** Baseline counts: 11 (Target) / 10 (Comparator)	Mid (8)	Percent Change*: -64	*.001*	Percent Change*: -50	*.01*	**NS**
	E.03.03			**Motretinide (qd)**		**Tretinoin**		
253 ↑ N=60 Parallel Mod/sev		**Papules (count)** Baseline counts: 10 (Target) / 7 (Comparator)	Mid (8)	Percent Change*: -50	*.01*	Percent Change*: -71	*.001*	**NS**
		Pustules (count) Baseline counts: 10 (Target) / 10 (Comparator)	Mid (8)	Percent Change*: -70	*.01*	Percent Change*: -50	*.01*	**NS**
	E.04.01			**Retinyl beta-glucuronide**		**Vehicle**		
145 ↑ N=29 Parallel Mild/mod		**Total lesions (ratio to initial)** Count location: Side of face (spilt face trial).	Short (4)	Measure: 1		Measure: 1		
		Total lesions change (ratio to initial) Count location: Side of face (split face trail).	Mid (12)	Measure: 1		Measure: 1		
		Overall change/physician (score) Count location: Side of face (spilt face trial).	Long (16	Measure: 3		Measure: 3		
		Inflammatory (count/median)	Long (18	Measure: 23	*.07*	Measure: 27	*NS*	
		Inflammatory change (ratio to initial)	Long (18	Measure: 1		Measure: 1		
		Non-inflammatory (count/median)	Long (18	Measure: 10	*.001*	Measure: 11	*.01*	
		Non-inflammatory change (ratio to initial)	Long (18	Measure: 0		Measure: 0		
		Total lesions (count/median)	Long (18	Measure: 28	*.002*	Measure: 41	*.06*	
		Total lesions change (ratio to intitial)	Long (18	Measure: 0		Measure: 1		
	E.04.02			**Retinyl beta-glucuronide**		**Tretinoin**		
146 ↑ N=15 Parallel Mild/mod		**Total lesions change (ratio to initial)** Count location: Side of face.	Short (6)	Measure: 1		Measure: 1		
		Total lesions change (ratio to initial)	Mid (8)	Measure: 1		Measure: 1		
		Inflammatory (count/median)	Long (28	Measure: 3		Measure: 6		
		Inflammatory lesion (ration to initial)	Long (28	Measure: 0		Measure: 0		
		Non-inflammatory (count/median)	Long (28	Measure: 4		Measure: 6		
		Non-inflammatory change (ratio to initial)	Long (28	Measure: 0		Measure: 0		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
146 ↑ N=15 Parallel Mild/mod		**Overall change/physician (score)** Count location: Side of face.	Long (28	Measure: 4	*.05*	Measure: 4	*.05*	
		Total lesions (count/median)	Long (28	Measure: 7		Measure: 10		**NS**
		Total lesions change (ratio to initial)	Long (28	Measure: 0		Measure: 0		**0.06**
	E.05.01			**Tretinoin**		**Polyoprepolymer-2**		
219 ↑ N=344 Parallel Mild/mod		**Inflammatory change (%)**	Short (4)	Percent change: -22		Percent change: -11		
		Non-inflammatory change (%)	Short (4)	Percent change: -25 (21.)		Percent change: -5		**NS**
		Total lesions change (%)	Short (4)	Percent change: -25 (21.)		Percent change: -7		
		Inflammatory change (%)	Mid (12)	Percent change: -48 (92.)		Percent change: -32 (92.)		
		Non-inflammatory change (%)	Mid (12)	Percent change: -48 (12.)		Percent change: -28		**NS**
		Total lesions change (%)	Mid (12)	Percent change: -49 (12.)		Percent change: -28		**NS**
	E.05.01			**Tretinoin (0.02%)**		**Vehicle**		
58 ↓ N=256 Parallel Sev		**Comedones severity (christiansen)** Count location: Worst area.	Short (4)	Measure: 118		Measure: 157		**0.05**
		Nodes+cysts (score)	Short (4)	Measure: 10		Measure: 18		**NS**
		Papules severity (christiansen)	Short (4)	Measure: 85		Measure: 108		**NS**
		Pustules (score)	Short (4)	Measure: 64		Measure: 87		**NS**
		Comedones (christiansen)	Mid (8)	Measure: 94		Measure: 131		**0.01**
		Nodes+cysts (score)	Mid (8)	Measure: 9		Measure: 14		**NS**
		Papules severity (christiansen)	Mid (8)	Measure: 76		Measure: 83		**NS**
		Pustules (score)	Mid (8)	Measure: 42		Measure: 67		**NS**
	E.05.01			**Tretinoin (0.025%)**		**Vehicle**		
198 ↑ N=60 Parallel		**Comedones (count)** Count location: 2.5 cm. Baseline counts: 29 (Target) / 20 (Comparator)	Mid (12)	Percent Change*: -62		Percent Change*: 25		
		Papules (count) Count location: 2.5 cm. Baseline counts: 10 (Target) / 12 (Comparator)	Mid (12)	Percent Change*: -80		Percent Change*: 317		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
198 ↑ N=60 Parallel		**Pustules (count)** Count location: 2.5 cm. Baseline counts: 2 (Target) / 2 (Comparator)	Mid (12)	Percent Change*: -87		Percent Change*: -65		
		Severity/patient (vas)	Mid (12)	Measure: 20		Measure: 39		
	E.05.01			**Tretinoin (0.05%)**		**Vehicle**		
58 ↓ N=256 Parallel Sev		**Comedones severity (christiansen)** Count location: Worst area.	Short (4)	Measure: 120		Measure: 157		**0.01**
		Nodes+cysts (score)	Short (4)	Measure: 20		Measure: 18		**NS**
		Papules severity (christiansen)	Short (4)	Measure: 92		Measure: 108		**0.05**
		Pustules (score)	Short (4)	Measure: 71		Measure: 87		**NS**
		Comedones (christiansen)	Mid (8)	Measure: 89		Measure: 131		**0.01**
		Nodes+cysts (score)	Mid (8)	Measure: 15		Measure: 14		**NS**
		Papules severity (christiansen)	Mid (8)	Measure: 61		Measure: 83		**0.05**
		Pustules (score)	Mid (8)	Measure: 35		Measure: 67		**NS**
198 ↑ N=60 Parallel		**Comedones (count)** Count location: 2.5 cm. Baseline counts: 18 (Target) / 20 (Comparator)	Mid (12)	Percent Change*: -59		Percent Change*: 25		
		Papules (count) Count location: 2.5 cm. Baseline counts: 8 (Target) / 12 (Comparator)	Mid (12)	Percent Change*: -65		Percent Change*: 317		
		Pustules (count) Count location: 2.5 cm. Baseline counts: 3 (Target) / 2 (Comparator)	Mid (12)	Percent Change*: -85		Percent Change*: -65		
		Severity/patient (vas)	Mid (12)	Measure: 18		Measure: 39		
	E.05.01			**Tretinoin (ethanol)**		**Vehicle**		
220 N=215 Parallel Mild/mod		**Inflammatory change (%)** Between P-value: vs vehicle.	Short (4)	Percent change: -41		Percent change: -19		**0.05**
		Inflammatory change (%)	Short (4)	Percent change: -25		Percent change: -18		**NS**
		Non-inflammatory change (%)	Short (4)	Percent change: -21		Percent change: -12		**NS**
		Total lesions change (%)	Short (4)	Percent change: -23		Percent change: -15		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
220 N=215 Parallel Mild/mod		**Non-inflammatory change (%)** Between P-value: vs vehicle.	Mid (12)	Percent change: -40		Percent change: -25		**0.05**
		Total lesions change (%)	Mid (12)	Percent change: -40		Percent change: -24		**0.05**
	E.05.01			**Tretinoin (polyoprepolymer-2)**		**Vehicle**		
220 N=215 Parallel Mild/mod		**Inflammatory change (%)**	Short (4)	Percent change: -20		Percent change: -18		**NS**
		Non-inflammatory change (%) Between P-value: vs tretinoin (polyoprepolymer 2).	Short (4)	Percent change: -24		Percent change: -12		**0.05**
		Total lesions change (%)	Short (4)	Percent change: -23		Percent change: -15		**NS**
		Inflammatory change (%)	Mid (12)	Percent change: -39		Percent change: -19		**0.05**
		Non-inflammatory change (%) Between P-value: vs vehicle.	Mid (12)	Percent change: -41		Percent change: -25		**0.05**
		Total lesions change (%)	Mid (12)	Percent change: -41		Percent change: -24		**0.05**
	E.05.01			**Tretinoin + polyoprepolymer-2**		**Polyoprepolymer-2**		
219 ↑ N=344 Parallel Mild/mod		**Inflammatory change (%)**	Short (4)	Percent change: -15		Percent change: -11		**NS**
		Non-inflammatory change (%)	Short (4)	Percent change: -18 (21.)		Percent change: -5		**NS**
		Total lesions change (%)	Short (4)	Percent change: -18 (21.)		Percent change: -7		
		Inflammatory change (%)	Mid (12)	Percent change: -46		Percent change: -32 (92.)		**NS**
		Non-inflammatory change (%)	Mid (12)	Percent change: -44 (12.)		Percent change: -28		**NS**
		Total lesions change (%)	Mid (12)	Percent change: -46 (12.)		Percent change: -28		**NS**
	E.05.02			**Tretinoin**		**Benzoyl peroxide**		
38 ↓ N=97 Parallel Mod		**Comedones (count)** Count location: Entire face. Baseline counts: 25 (Target) / 38 (Comparator)	Mid (12)	Percent Change*: -88	*.001*	Percent Change*: -53	*.001*	**0.01**
		Papules (count) Count location: Entire face. Baseline counts: 42 (Target) / 44 (Comparator)	Mid (12)	Percent Change*: -59	*.001*	Percent Change*: -38	*.001*	**0.01**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
38 ↓ N=97 Parallel Mod		**Pustules (count)** Count location: Entire face. Baseline counts: 8 (Target) / 10 (Comparator)	Mid (12)	Percent Change*: -68	*.001*	Percent Change*: -63	*.001*	**NS**
	E.05.02			**Tretinoin**		**Benzoyl peroxide (acetone)**		
221 ↓ N=147 Parallel Mod		**Comedones (count)** Baseline counts: 27 (Target) / 23 (Comparator)	Short (6)	Percent Change*: -52		Percent Change*: -61		**NS**
		Papules (count) Count location: Withouski/simon. Baseline counts: 8 (Target) / 9 (Comparator)	Short (6)	Percent Change*: -25		Percent Change*: -67		**NS**
		Pustules (count) Baseline counts: 4 (Target) / 4 (Comparator)	Short (6)	Percent Change*: -44		Percent Change*: -83		**NS**
		Comedones change (%)	Mid (8)	Percent change: -63		Percent change: -62		**NS**
		Papules change (%)	Mid (8)	Percent change: -29		Percent change: -56		**0.02**
		Pustules change (%)	Mid (8)	Percent change: -48		Percent change: -80		**NS**
	E.05.02			**Tretinoin**		**Benzoyl peroxide (alcohol)**		
221 ↓ N=147 Parallel Mod		**Comedones change (%)**	Mid (8)	Percent change: -63		Percent change: -57		**NS**
		Papules change (%)	Mid (8)	Percent change: -29		Percent change: -56		**0.02**
		Pustules change (%)	Mid (8)	Percent change: -48		Percent change: -79		**NS**
	E.05.04			**Tretinoin**		**Azelaic acid**		
188 ↑ N=289 Parallel		**Comedones (count/median)**	Mid (12)	Measure: 18		Measure: 22		**NS**
		Comedones (count) Baseline counts: 52 (Target) / 50 (Comparator)	Long (20	Percent Change*: -81		Percent Change*: -78		**NS**
	E.05.04			**Tretinoin + vehicle**		**Azelaic acid + glycolic acid**		
316 N=70 Parallel Mild		**Dryness (severity)**	Short (4)	Measure: 1 (1.6)		Measure: 0 (1.6)		**0.01**
		Erythema (severity)	Short (4)	Measure: 1 (1.4)		Measure: 1 (1.4)		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
316 N=70 Parallel Mild		**Inflammatory change (%)**	Short (4)	Percent change: -23		Percent change: -46 (36.)		
		Non-inflammatory change (%)	Short (4)	Percent change: -32		Percent change: -18		
		Papules change (%)	Short (4)	Percent change: -23		Percent change: -45 (43.)		
		Scaling (severity)	Short (4)	Measure: 0 (0.9)		Measure: 0 (0.9)		**0.007**
		Dryness (severity)	Mid (12)	Measure: 0 (0.9)		Measure: 0 (0.9)		**NS**
		Erythema (severity)	Mid (12)	Measure: 1 (2.)		Measure: 0 (2.)		**0.026**
		Inflammatory change (%)	Mid (12)	Percent change: -28 (120.)		Percent change: -55 (120.)		**NS**
		Non-inflammatory change (%)	Mid (12)	Percent change: -46		Percent change: -47		**NS**
		Papules change (%)	Mid (12)	Percent change: -23 (132.)		Percent change: -55 (132.)		**0.03**
		Scaling (severity)	Mid (12)	Measure: 0 (2.)		Measure: 0 (2.)		**0.001**
	E.05.07			**Tretinoin (0.02%)**		**Tretinoin (0.05%)**		
58 ↓ N=256 Parallel Sev		**Comedones severity (christiansen)** Count location: Worst area.	Short (4)	Measure: 118		Measure: 120		**0.05**
		Nodes+cysts (score)	Short (4)	Measure: 10		Measure: 20		**NS**
		Papules severity (christiansen)	Short (4)	Measure: 85		Measure: 92		**NS**
		Pustules (score)	Short (4)	Measure: 64		Measure: 71		**NS**
		Comedones (christiansen)	Mid (8)	Measure: 94		Measure: 89		**0.01**
		Nodes+cysts (score)	Mid (8)	Measure: 9		Measure: 15		**NS**
		Papules severity (christiansen)	Mid (8)	Measure: 76		Measure: 61		**NS**
		Pustules (score)	Mid (8)	Measure: 42		Measure: 35		**NS**
	E.05.07			**Tretinoin (0.025%)**		**Tretinoin (0.05%)**		
198 ↑ N=60 Parallel		**Comedones (count)** Count location: 2.5 cm. Baseline counts: 29 (Target) / 18 (Comparator)	Mid (12)	Percent Change*: -62		Percent Change*: -59		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
198 ↑ N=60 Parallel		**Papules (count)** Count location: 2.5 cm. Baseline counts: 10 (Target) / 8 (Comparator)	Mid (12)	Percent Change*: -80		Percent Change*: -65		
		Pustules (count) Count location: 2.5 cm. Baseline counts: 2 (Target) / 3 (Comparator)	Mid (12)	Percent Change*: -87		Percent Change*: -85		
		Severity/patient (vas)	Mid (12)	Measure: 20		Measure: 18		
	E.05.07			**Tretinoin (polyoprepolymer-2)**		**Tretinoin (ethanol)**		
220 N=215 Parallel Mild/mod		**Inflammatory change (%)**	Short (4)	Percent change: -20		Percent change: -25		**NS**
		Non-inflammatory change (%) Between P-value: vs tretinoin (polyoprepolymer 2).	Short (4)	Percent change: -24		Percent change: -21		**0.05**
		Total lesions change (%)	Short (4)	Percent change: -23		Percent change: -23		**NS**
		Inflammatory change (%)	Mid (12)	Percent change: -39		Percent change: -41		**0.05**
		Non-inflammatory change (%) Between P-value: vs vehicle.	Mid (12)	Percent change: -41		Percent change: -40		**0.05**
		Total lesions change (%)	Mid (12)	Percent change: -41		Percent change: -40		**0.05**
	E.05.07			**Tretinoin + polyoprepolymer-2**		**Tretinoin**		
219 ↑ N=344 Parallel Mild/mod		**Inflammatory change (%)**	Short (4)	Percent change: -15		Percent change: -22		**NS**
		Non-inflammatory change (%)	Short (4)	Percent change: -18 (21.)		Percent change: -25 (21.)		**NS**
		Total lesions change (%)	Short (4)	Percent change: -18 (21.)		Percent change: -25 (21.)		
		Inflammatory change (%)	Mid (12)	Percent change: -46		Percent change: -48 (92.)		**NS**
		Non-inflammatory change (%)	Mid (12)	Percent change: -44 (12.)		Percent change: -48 (12.)		**NS**
		Total lesions change (%)	Mid (12)	Percent change: -46 (12.)		Percent change: -49 (12.)		**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	E.05.08			**Tretinoin**		**Methyl prednisolone + neomycin**		
13 N=68 Parallel split face Mild/mod/sev		**Change (gprg)**	Short (4)	Measure: 98		Measure: 88		
		Change (gprg)	Short (4)	Measure: 98		Measure: 88		
		Change (gprg)	Mid (8)	Measure: 126		Measure: 120		
		Change (gprg)	Mid (8)	Measure: 126		Measure: 120		
		Comedones (count)	Mid (8)	Raw count: 7		Raw count: 7		
		Comedones (count)	Mid (8)	Raw count: 7		Raw count: 7		
	E.05.09			**Tretinoin**		**Chloramphenical + hydrocortisone**		
37 ↑ N=56 Parallel Mod		**Comedones change (count)** Count location: 5cm diameter. Baseline counts: 6 (Target) / 5 (Comparator)	Short (6)	Percent change*: -99		Percent change*: -60		
		Comedones change (count)	Short (6)	Percent change*: -99		Percent change*: -60		
		Cysts change (count) Count location: 5 cm diameter. Baseline counts: 1 (Target) / 0 (Comparator)	Short (6)	Percent change*: -67		Percent change*: -46		**NS**
		Cysts change (count)	Short (6)	Percent change*: -67		Percent change*: -46		**NS**
		Papules change (count) Count location: 5 cm diameter. Baseline counts: 7 (Target) / 6 (Comparator)	Short (6)	Percent change*: -42		Percent change*: -27		
		Papules change (count)	Short (6)	Percent change*: -42		Percent change*: -27		
		Pustules change (count) Count location: 5 cm diameter. Baseline counts: 2 (Target) / 2 (Comparator)	Short (6)	Percent change*: -62		Percent change*: -72		
		Pustules change (count)	Short (6)	Percent change*: -62		Percent change*: -72		
		Comedones change (count) Count location: 5 cm diameter. Baseline counts: 6 (Target) / 5 (Comparator)	Mid (12)	Percent change*: -76	*.001*	Percent change*: -81	*.001*	**NS**
		Comedones change (count)	Mid (12)	Percent change*: -76	*.001*	Percent change*: -81	*.001*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
37 ↑ N=56 Parallel Mod		**Cysts change (count)** Count location: 5 cm diameter. Baseline counts: 1 (Target) / 0 (Comparator)	Mid (12)	Percent change*: -82	*.001*	Percent change*: -46		**NS**
		Cysts change (count)	Mid (12)	Percent change*: -82	*.001*	Percent change*: -46		**NS**
		Overall change/patient (vas) Count location: 5 cm diameter.	Mid (12)	Measure: -4 (2.4)	*.001*	Measure: -3 (4.6)	*.001*	**NS***
		Overall change/patient (vas)	Mid (12)	Measure: -4 (2.4)	*.001*	Measure: -3 (4.6)	*.001*	**NS***
		Papules change (count) Count location: 5 cm diameter. Baseline counts: 7 (Target) / 6 (Comparator)	Mid (12)	Percent change*: -47		Percent change*: -47		**NS**
		Papules change (count)	Mid (12)	Percent change*: -47		Percent change*: -47		**NS**
		Pustules change (count) Count location: 5 cm diameter. Baseline counts: 2 (Target) / 2 (Comparator)	Mid (12)	Percent change*: -83	*.001*	Percent change*: -78	*.001*	**NS**
		Pustules change (count)	Mid (12)	Percent change*: -83	*.001*	Percent change*: -78	*.001*	**NS**
	E.06.01			**Vitamin A**		**Vehicle**		
35 ↑ N=72 Parallel Mild/mod		**Comedones (group count)** Count location: Witkowski/simons.	Mid (12)	Percent Change*: -66		Percent Change*: -42		
		Comedones [female] (count) Count location: Witkowski/simons. Baseline counts: 272 (Target) / 370 (Comparator)	Mid (12)	Percent Change*: -64		Percent Change*: -35		
		Comedones [male] (count) Count location: Witkowski/simons. Baseline counts: 1042 (Target) / 722 (Comparator)	Mid (12)	Percent Change*: -67		Percent Change*: -46		
		Papules (group count) Count location: Witkowski/simons.	Mid (12)	Percent Change*: -26		Percent Change*: -49		
		Papules [female] (group count)	Mid (12)	Percent Change*: -12		Percent Change*: -13		
		Papules [male] (group count)	Mid (12)	Percent Change*: -66		Percent Change*: -30		
		Pustules (total count)	Mid (12)	Percent Change*: -68		Percent Change*: -67		
		Pustules [female] (total count)	Mid (12)	Percent Change*: -94		Percent Change*: -92		
		Pustules [male] (total count)	Mid (12)	Percent Change*: -60		Percent Change*: -62		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	E.06.02			**Vitamin A**		**Sulfur + resorcinol**		
272 N=189 Parallel		**Total lesions change (%)** Count location: Left side.	Long (14	Percent change: -62		Percent change: -16		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.